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PENYARINGAN PESAKIT NASOPHARYNGEAL CARCINOMA 
DI MALAYSIA MENGGUNAKAN TEKNIK PERBANDINGAN 
HIBRIDASI GENOMIK UNTUK MENGENALPASTI 
PERUBAHAN GENETIK YANG SPESIFIK 
  
ABSTRAK 
Kanser nasofaring (NPC) adalah kanser yang berasal daripada lapisan epitelium 
lekuk-rosen Muller pada nasofarink. Kanser ini banyak terdapat di China Selatan 
dan  Asia Tenggara termasuk Malaysia. Di dalam kajian ini, perubahan genetik pada 
empat puluh empat pesakit NPC daripada  5 buah hospital di Malaysia telah disaring. 
Teknik hibridasi perbandingan genomik (CGH) telah digunakan 
untuk pengenalpastian sebarang perubahan genetik. CGH adalah salah satu teknik 
sitogenetik molekul yang digunakan untuk mengenalpasti ketidakstabilan perubahan 
genetik yang terdapat pada penyakit kanser ini. Tisu biopsi nasofarink 
yang dipilih telah dipastikan mengandungi sekurang-kurangnya 75% tumor terlebih 
dahulu dengan menggunakan teknik pewarnaan Haematoxylin & Eosin (H&E) 
sebelum penggunaan teknik CGH. DNA tumor telah diekstrak daripada empat puluh 
empat biopsi NPC, sementara empat puluh empat DNA rujukan telah diekstrak 
daripada empat puluh empat darah periferi dari subjek normal. DNA tumor dan DNA 
normal telah dilabel dengan kaedah translasi nick (nick translation) menggunakan 
pewarnaan berpendarfluor hijau dan merah. DNA itu telah dihibridasi pada metafasa 
kromosom dan diwarnakan dengan DAPI II. Akhirnya, gambar kromosom telah 
diambil dan dianalisa.Kebanyakan sampel adalah lelaki berbanding perempuan 
dengan kadar 2.4:1. Kumpulan etnik Melayu mempunyai peratus yang lebih tinggi 
xxviii 
 
daripada Cina iaitu masing-masing 57% dan 43%. Kes NPC dari kalangan Cina 
menunjukkan insiden yang tinggi pada dua buah hospital di negeri yang mempunyai 
penduduk Cina yang tinggi iaitu Johor dan Pahang. Purata umur pesakit pada 
diagnosis pesakit NPC ialah 49.45 tahun (14.74) [purata (SD)]. Tiada asosiasi yang 
signifikan ditemui di antara umur dengan jantina dan kumpulan etnik. Kebanyakan 
pesakit (38 pesakit) adalah daripada klasifikasi WHO Jenis III kecuali 5 pesakit 
adalah WHO jenis II dan seorang pesakit adalah WHO jenis I. Tiada asosiasi yang 
signifikan di antara jenis WHO dengan kumpulan etnik dan dengan jantina pesakit 
NPC. Analisa juga menunjukkan tiada asosiasi yang signifikan di antara jenis WHO 
dengan purata umur pesakit NPC. Di dalam kajian ini, perubahan kromosom pada 41 
kes telah dijumpai manakala 3 kes tiada perubahan kromosom. Lima belas perubahan 
penambahan kromosom yang lazim telah dikenalpasti iaitu kromosom 2p, 2q, 3p, 3q, 
4p, 4q, 5p, 5q, 6q, 7q, 8q, dan 12q manakala 10 perubahan pengurangan kromosom 
yang lazim telah dijumpai iaitu 1p, 9q, 15q, 16p, 16q, 17p, 19p, 19q, dan 12q. 
Tiada asosiasi yang signifikan ditemui di antara jantina dan penambahan genetik 
kecuali kromosom 3q manakala dalam perubahan pengurangan kromosom, 
terdapat asosiasi yang signifikan pada 4 daripada 10 kromosom iaitu pada 
kromosom  1p (p=0.013), 15q (p=0.012), 16q (p=0.040) dan 19p 
(p=0.033). Asosiasi yang signifikan juga tidak ditemui di antara 3 jenis NPC dengan 
perubahan genetik yang lazim. Pengesahan menggunakan teknik jujukan hibridasi 
perbandingan genomik (aCGH) menunjukkan hasil yang sepadan dengan teknik 
CGH secara konvensional. Berdasarkan artikel yang sedia ada, kajian ini adalah yang 
pertama dijalankan terhadap pesakit NPC di Malaysia dengan menggunakan teknik 
CGH. Dari kajian ini, beberapa onkogen dan gen penindas tumor telah dipetakan 
pada perubahan kromosom yang lazim seperti c-myc onkogen pada 8q24, MDM2 
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onkogen pada 12q13-14 dan TSC2 gen penindas tumor pada 16p. Kajian ini telah 
menyediakan landasan kepada kajian seterusnya untuk menempatkan sebarang gen 
penindas tumor  dan onkogen pada pesakit NPC di Malaysia. Untuk mengenalpasti 
sebarang gen penindas tumor dan onkogen pada pesakit NPC di Malaysia, saiz 
sampel haruslah ditingkatkan lagi pada kajian masa hadapan. 
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SCREENING OF MALAYSIAN PATIENTS WITH 
NASOPHARYNGEAL CARCINOMA (NPC) USING 
COMPARATIVE GENOMIC HYBRIDIZATION (CGH) 
TECHNIQUE FOR IDENTIFICATION OF SPECIFIC GENETIC 
ALTERATION 
 
ABSTRACT 
Nasopharyngeal Carcinoma (NPC) is a malignancy that originates from the epithelial 
lining of Fossa of Rosen Muller in the nasopharynx. It is a highly prevalent disease 
in Southern China and Southeast Asia including Malaysia. In this study, the genetic 
alterations from forty-four NPC patients from five hospitals in Malaysia were 
screened. Comparative Genomic Hybridization (CGH) technique was used for 
screening the genetic alterations. CGH is a molecular cytogenetic technique which is 
used to identify imbalanced genetic alterations that is present in this malignant 
disease. NPC tissues that were biopsied were first confirmed to have at least 75% 
tumour cells using Haematoxylin & Eosin (H & E) staining before proceeding to 
CGH. Tumor cells were extracted from forty-four NPC biopsies while forty-four 
references DNA were extracted from peripheral blood of forty-four normal controls. 
Tumour DNA and normal DNA was labelled by nick translation method with green 
and red fluorescent dyes. They were hybridized at metaphase chromosomes DNA 
and counterstained with DAPI II. Finally, the image was captured and analyzed. 
Most of the samples were male compared to female with a ratio of 2.4 : 1. Malay 
ethnic group was higher than Chinese which is 57% and 43% respectively. Chinese 
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cases showed higher incidence in the two hospitals from the states with majority 
Chinese ethnic group.  The mean age of diagnosis of the NPC patients is 49.45 years 
old (14.74) [mean (SD)]. There were no significant difference between age with 
gender and ethnicity.  Most of the patients (38 patients) were NPC WHO Type III 
except 5 patients who were Type II and one Type I. There is no significant difference 
between WHO type with ethnic group and with gender of NPC patients.  There is 
also no correlation between types of NPC with mean age of diagnosis. In this study, 
chromosomal alterations were found in 41 cases but none in 3 other cases. Fifteen 
common chromosomal alterations gains which were chromosome arms 2p, 2q, 3p, 
3q, 4p, 4q, 5p, 5q, 6q, 7q, 8q and 12p while ten common chromosomal alterations 
loss were 1p, 9q, 15q, 16p, 16q, 17p, 19p, 19q and 22q. There were no genetic 
differences between the gender and genetic gain except for chromosome 3q while in 
chromosomal aberration loss there were genetic differences in 4 out of 10 
chromosome arm which were chromosome arms 1p (p=0.013), 15q (p=0.012), 16q 
(p=0.040) and 19p (p=0.033). In addition, there were no genetic differences between 
the three types of NPC with common genetic alterations findings except for 
chromosome 9q loss. Loss of 9q was detected in 80% of Type II and 32% of Type III 
tumours. Validation using Array Comparative Genomic Hybridization (aCGH) 
showed compatible results with conventional CGH. Based on the available literature, 
this is the first study conducted on Malaysian NPC patients utilizing CGH technique. 
From this study, several oncogenes and tumour suppressor genes were mapped at our 
common genetic alterations such as c-myc oncogene at 8q24, MDM2 oncogene at 
12q13-14 and TSC2 tumour suppressor gene at 16p. This study has provided the 
platform for further investigations to locate any tumour-suppressor genes and 
oncogenes in Malaysian NPC patients. In order to determine any tumour-suppressor 
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genes and oncogenes in Malaysian NPC patients, it is suggested that a larger sample 
size of NPC patients should be conducted in future research. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Background of the study  
Genetic factors have been reported as one of the most important etiological factors of 
Nasopharyngeal Carcinoma, but the molecular basis for tumorigenesis is still 
unclear. Therefore, screening of genetic imbalances in patients with NPC would be 
useful for early diagnosis of NPC. In this study, Comparative Genomic Hybridisation 
(CGH) was used to detect genetic alterations that include gain or loss in the 
chromosomes of NPC tissues and validation by array-based Comparative Genomic 
Hybridization (aCGH) was utilized. Prior to make further explanation of this study, 
clear information about NPC and CGH are needed.  
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1.2 General description of the nasopharynx 
The nasopharynx is a portion of the pharynx that lies behind the nasal cavity and 
above the soft palate. According to medical dictionary, the word ‘nasopharynx’ is 
derived from a combination of Latin and Greek. ‘Naso-’ is derived from the Latin 
word nasus, which means nose while ‘Pharynx’ is from a Greek word for throat and 
the Greco-Roman term ‘nasopharynx’ was used in 1877 (Shiel and Stoppler, 2008a). 
Nasopharynx is the uppermost division of the pharynx while oropharynx is the 
middle part, followed by hypopharynx which is the third part of the pharynx (Figure 
1.1). The air inhaled from atmosphere through the nose crosses the nasopharynx and 
enters the trachea for respiration.  
 
The size of the nasopharynx in adults is approximately 4cm in length, 4 cm wide and 
3 cm in an anteroposterior dimension (Chew, 1997). The nasopharynx consists of an 
anterior wall, floor, lateral wall, roof and posterior wall. The anterior wall of the 
nasopharynx is formed by the choana and posterior margin of the nasal septum. The 
floor is formed by the upper surface of the soft palate and is continued into the 
oropharynx.  The lateral wall on either side in bony and presents two important 
features, which the pharyngeal orifice of the Eustachian tubes and the fossae of 
Rosenmuller. The roof continues into posterior wall separate smoothly and lies on 
the body of sphenoid, basiocciput and basisphenoid (Chew, 1997).  
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Figure 1.1: Schematic diagram of nasopharynx. Nasopharynx is the uppermost 
division of the pharynx (www.aboutcancer.com/nasopharynx). 
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1.3 Neoplasm 
Neoplasm or tumor is abnormal cell growth which may be benign, pre-malignant 
(carcinoma in-situ) or malignant (cancer). According to the medical dictionary (Shiel 
and Stoppler, 2008a) the word ‘neoplasm’ is adapted from Greek which is ‘neo’ 
means new and plasma means growth. Thus, it is translated as a new growth. 
 
Neoplasm is classified as benign, premalignant and malignant. Benign neoplasm 
consists of non-cancerous cell that are unable to metastasize or invade to surrounding 
tissue. Pre-malignant neoplasm or carcinoma in-situ is tissue that has potential to be 
transformed into malignant cells after certain duration of time (Chabner, 2007). 
These forms of tissue are not invasive unless they are transformed into malignant 
tissues. Malignant cells have the quality to invade the surrounding tissues and 
destroy them. Moreover, they have the property to metastasize locally, regionally or 
to distant organs of the body.  
 
1.4 Cancer 
Cancer is a disease where the growth of the cells are beyond control (Crosta, 2010). 
When they grow, they do not push the surrounding structures but rather they 
infiltrate and invade into them, causing the disruption of their normal walls, surfaces, 
borders and boundaries. This does not limits to the soft tissues only, but most of them 
even erode the surrounding bony contours and destroy the anatomical land marks. 
Another hallmark is spread to other locations via lymphatics or blood vessels and 
metastazing into the distant organs of the body. There are many types of cancers 
depending upon where the cells are initially affected such as cervical cancer, 
colorectal cancer, lung cancer and nasopharyngeal cancer.  
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Cancer cells are formed when these two processes which are mitosis and protein 
synthesis, are disturbed. The character of cancer cells are anaplastic which make the 
cells failed to carry on the function of mature cells when their DNA stops making 
codes (Chabner, 2007). In normal cell cycle regulation, normal cells will become 
mature and die after certain time via a process called apoptosis. In cancer cells, the 
mechanism of apoptosis also breaks down making the cells reproduce continuously. 
Apoptosis or programmed cell death makes the uncontrolled cell growth that leads to 
a mass formation(Crosta, 2010). Besides, altered DNA materials and cellular 
programs make new signals that enables cell proliferation, movement of cells, 
invasion of adjacent tissue and metastases (Chabner, 2007). 
 
The cause of the cancer development can be divided into two major groups which are 
genetic hereditary and environmental factors (Chabner, 2007). Preetha Anand et. al. 
reported that, environmental factor plays an important role of causing cancer (Anand 
et al., 2008). About 90-95% of all cancer cases can be attributed to environment and 
lifestyle, while only 5-10% are attributed to genetic hereditary factors (Anand et al., 
2008). Therefore, major lifestyle changes such as smoking cessation, increased 
ingestion of fruits and vegetables, moderate use of alcohol, caloric restriction, 
exercise, avoidance of direct exposure to sunlight, minimal meat consumption, use of 
whole grains, use of vaccinations, and regular check-ups are needed to prevent 
cancer development and progression (Anand et al., 2008). 
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1.4.1 Classification of Cancerous Tumour 
Cancer is classified into three major groups which are carcinoma, sarcoma and 
mixed-tissue tumours. They are divided according to histogenesis which is by 
identifying from where the particular tumours cell arise (Chabner, 2007). 
Carcinomas are the largest group that contribute approximately 90% of all 
malignancies. It is a solid tumour that is derived from epithelial tissue that covers 
internal and external body organs such as skin, urinary, colon, and reproductive 
organs. Benign tumours that are derived from epithelial cells are usually designated 
with the term adenoma, while malignant tumours that are derived from epithelial 
tissue are designated the term carcinoma (Chabner, 2007). 
 
Sarcomas are derived from connective tissue and are less common than carcinomas. 
Examples of connective tissue are bone, fat, muscle and bone marrow. While mixed-
tissue tumours are uncommon tumours which are derived from tissue that composed 
of epithelial and connective tissue such as kidney, ovaries and testes. 
 
1.4.2 Cancer in Malaysia 
According to the Malaysia Cancer Statistic 2006, 131.3 per 100,000 Malaysians were 
diagnosed as having cancer and NPC is one of the most common cancers in 
Peninsular Malaysia after breast, colorectal, lung and cervical cancer (Zainal et al., 
2006). The variation of cancer gives the difference in cancer occurrence of age, 
ethnicity, and sex. Certain types of cancer mainly occur in certain age group, 
ethnicity and sex. The most common cancer in children (from age 0-14 years old) is 
leukaemia. The most common cancer in men are nasopharynx, colorectal, lung, brain 
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and leukaemia while the most common cancer in women are breast, cervix, thyroid 
gland, ovary and colorectal (Zainal et al., 2006). 
 
1.5 Nasopharyngeal Carcinoma (NPC) 
Nasopharyngeal carcinoma (NPC) is a malignancy originating in the epithelial lining 
of the nasopharynx, commonly arising from the fossa of Rosenmuller, the recess 
located medial to the medial cruca of the Eustachian tube (Wei and Sham, 2005). 
Figure 1.2 shows the Computerized Tomography (CT) image of nasopharyngeal 
carcinoma. It is one of the most common cancers in Malaysia, a country in Southeast 
Asia with a multiracial population (Prasad and Rampal, 1992). In Malaysia, the 
National Cancer Registry stated that NPC was the second most common cancer in 
men: Chinese men had the highest age-standardised incidence, with 18.1 cases per 
100,000, Malay men, with 4.8 cases per 100,000, and Indian men, with 2.6 cases per 
100,000 (Lim et al., 2004). According to Watkinson et. al., the incidence of 
nasopharyngeal cancer in Singapore was 87% among the Chinese, 10% among 
Malays, 3% among Europeans, and negligible in the Indian population (Watkinson et 
al., 2000). Whereas in Hong Kong in the southern part of the Guangdong, the 
incidence rate of NPC among men and women are 20-30 per 100, 000 and 15 to 20 
per 100,000 respectively (Parkin et al., 1997). The high incidence of NPC among the 
Chinese ethnic group still remains unknown when they immigrated to Southeast Asia 
and North American countries but conversely when they were born in North America 
(Dickson and Flores, 1985). Wei and Sham suggested that this incidence may be 
related to genetic, ethnic and environmental factor (Wei and Sham, 2005).  
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Figure 1.2: CT image of NPC. The arrow shows the nodular tumour abutting the left 
pterygoid process (Shatzkes et al., 2006). 
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1.5.1 Clinical features of NPC 
NPC patients usually presents with multiple symptoms. However early tumour may 
remain asymptomatic due to the anatomy of the nasopharynx which has the space 
that allows air passages (Woo and Van Hasselt, 2008). This may cause difficulty to 
examine the tumour at an early stage. According to a study in Hong Kong, the 
commonest clinical presentation of NPC is cervical lymphadenopathy where 76% of 
NPC patients complaints of neck swelling, followed by nasal symptoms 73%, aural 
symptoms 62% and cranial nerve palsy in 20% of the patients (Lee et al., 1997). This 
is similar with a study in Malaysia where the commonest symptoms reported which 
are neck swelling (57%), followed by nasal bleeding (45%) and headache (41%) 
(Suzina and Hamzah, 2003).  
 
Patients with NPC present one or more symptoms which depend on the location of 
the primary tumour, their infiltration of the structures and the metastases to the 
cervical lymph nodes (Wei and Sham, 2005). At the beginning, a tumour mass can 
lead to unilateral nasal obstruction and discharge. The symptoms become bilateral 
and presents with epistaxis when the tumour grows and ulcerates (Wei and Sham, 
2005). The Eustachian tube becomes dysfunctional and presents with conductive 
deafness when the tumour bulk in the nasopharynx extends with or without 
posterolateral extension into the paranasopharyngeal space (Wei and Sham, 2005).  
 
The patient become the symptomatic when the primary tumour grows superiorly to 
infiltrate the skull base while diplopia is present when the tumour extends upwardly 
which affects the cavernous sinus, the lateral wall, the third, fourth and sixth cranial 
nerves (Wei and Sham, 2005). The patient will complaint of having facial pain and 
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numbness when the tumour extends to the foramen ovale which affects the fifth 
cranial nerve (Wei and Sham, 2005). Whilst the commonest complain arise is neck 
mass formation due to metastasizes of the tumour to the regional cervical lymph 
nodes (Wei and Sham, 2005). 
 
1.5.2 Incidence of NPC 
In Malaysia, NPC was the most common cancer among men (Zainal et al., 2006). 
The Age Standardized Rate (ASR) of 8.5 and 2.6 per 100,000 populations for males 
and females, respectively were registered as NPC. The incidence rate among Chinese 
males was the highest with the ASR of 15.9 per 100,000 populations (Zainal et al., 
2006). In Southern China, NPC was the serious health problem with the incidence 
rate of approximately 25-30 per 100 000 population which was the highest rate 
worldwide (Lo et al., 2004). While in Taiwan, NPC was estimated to be in the top 
ten ranking of incidence and cause of death from cancer (Chen et al., 1999). 
 
1.5.3 Histopathology of NPC 
NPC is composed of  malignant epithelial cells in which their nuclei are round or 
oval with scanty chromatin and distinct nucleoli (Wei and Sham, 2005). NPC is also 
known as malignant lymphoepithelioma because the tumour cells frequently infiltrate 
with lymphoid cells in the nasopharynx (Woo and Van Hasselt, 2008). Besides, there 
are many term have been used to describe these tumour cells such as undifferentiated 
carcinoma, transitional cell carcinoma and anaplastic carcinoma (Woo and Van 
Hasselt, 2008). Therefore, different histological classifications of NPC were used to 
classify this tumour (McGuire and Lee, 1990). 
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Since 1978 till now, NPC classification was based on the WHO (Shanmugaratnam, 
1978) classification which is divided into three histological subtypes type I, II and III 
on the basis of the light microscopic appearance (Woo and Van Hasselt, 2008). Type 
I is either squamous cell carcinoma or keratinizing carcinoma with well 
differentiated, moderately differentiated and poorly differentiated while type II is 
nonkeratinizing carcinoma and type III is undifferentiated carcinoma. The WHO 
(Shanmugaratnam and Sobin, 1991) classification was revised then in the same year 
into two grades. Grade 1 consist of type I, keratinizing squamous cell carcinoma and 
grade 2 consist of type II and type III which is nonkeratinizing squamous cell 
carcinoma and undifferentiated carcinoma (Woo and Van Hasselt, 2008). 
  
WHO type I NPC (Figure 1.3) showed the squamous differentiation with 
intercellular bridges and keratin over most of its extent while WHO type II (Figure 
1.4) showed the differentiation with a maturation sequence in the cells 
(Shanmugaratnam et al., 1979). There was no squamous differentiation, mucin 
production and granular differentiation shown in type II NPC (Shanmugaratnam et 
al., 1979). Shanmugaratnam  et. al., also described that type II NPC cells consist of 
fairly well defined cells and show an arrangement that is stratified or pavemented 
and not syncytial (Shanmugaratnam et al., 1979). Shanmugaratnam et. al. also 
described the histology of Type III NPC (Figure 1.5) as oval or round vesicular 
nuclei and prominent nucleoli which were arranged in irregular and moderately well 
defined masses. Moreover, it was formed in strands of loosely connected cells in 
lymphoid stroma (Shanmugaratnam et al., 1979). Contrary to type II tumour, type III 
cell margins are indistinct, shows mucin production and the tumour shows a 
syncytial and not pavemented appearance (Shanmugaratnam et al., 1979). It also 
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shows the spindle-shaped tumour cells with some of them showing hyperchromatin 
nuclei (Shanmugaratnam et al., 1979).  
 
Previous study showed that NPC grade 2 are higher than grade 1 in high incidence 
area such as Taiwan and Southeast Asia which was about 90% of all cases (Chen et 
al., 1999, Jayasurya et al., 2000). While NPC grade 1 was more common in low 
incidence area such as North America (Nicholls, 1997). Grade 2 is more related to 
EBV virus which can be detected within the tumour cells and in the peripheral 
circulation of patients (Woo and Van Hasselt, 2008). Contrary to grade 1 tumour 
which s not related to the EBV virus, they are less aggressive than grade 2 tumours 
and less sensitive to radiotherapy treatment (Woo and Van Hasselt, 2008).    
 
1.5.4 Staging of NPC 
Many stages of NPC have been designed for better correlation with prognosis. The 
staging is based on the combined assessment of patient’s tumour in nasopharynx (T), 
regional lymph nodes (N) and presence of any distant metastases (M) (Woo and Van 
Hasselt, 2008). The American Joint Committee on Cancer/ Union Internationale 
Contre le Cancer (AJCC/ UICC) system 1997 was preferred as the latest system 
should be used replacing the Ho’s staging system (Ho, 1978) even though Ho’s 
system is more effective in stratifying patients evenly into different prognostic group 
(Woo and Van Hasselt, 2008). Moreover, the new staging system allows the disease 
to be staged more precisely according to the extensiveness of the stage that separate 
patient into cohorts of more equal size and shown to predict survival (Cooper et al., 
1998, Chiu et al., 2003). The differential systems between AJCC/UICC stage and Ho 
stage is that the nodal classification of Ho stage indicates better prognostic 
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significance (Wei and Sham, 2005). The AJCC/UICC stage is shown in Table 1.1. 
The staging procedure is decided by the physician based on physical examination, 
endoscopy of the upper airway and radiological imaging by CT and/or MRI. These 
are different from other head and neck cancer which need evaluation under general 
anaesthesia (Woo and Van Hasselt, 2008). 
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Figure 1.3: Schematic diagram of keratinizing squamous cell carcinoma of 
nasopharyngeal carcinoma, WHO classification type I. This type is characterized by 
the presence of keratinization and intercellular bridge (Woo and Van Hasselt, 2008). 
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Figure 1.4: Schematic diagram of non-keratinizing carcinoma of NPC tissue, WHO 
classification type II. This type II is characterized by the presence of interconnecting 
cord of neoplastic cells and the absence of keratinisation 
(http://www.orthopaedia.com/display/PORT/Nasopharyngeal+Carcinoma) 
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Figure 1.5: Schematic diagram of undifferentiated carcinoma of nasopharyngeal 
carcinoma tissue, WHO classification type III. This type III is characterized by the 
cohesive growth of neoplastic cells, enlarged nuclei with vesicular chromatin, poorly 
defined cell margins and prominent nuleolei 
(http://www.pathconsultddx.com/pathCon/diagnosis). 
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CLASSIFICATION 
PRIMARY TUMOUR (T) 
TX PRIMARY TUMOUR CANNOT BE ASSESSED 
T0 NO EVIDENCE OF PRIMARY TUMOUR 
TIS CARCINOMA IN SITU 
T1 TUMOUR CONFINED TO THE NASOPHARYNX 
T2 TUMOUR EXTENDS TO SOFT TISSUES 
T2A TUMOUR EXTENDS TO THE OROPHARYNX AND/OR NASAL CAVITY WITHOUT PARAPHARYNGEAL 
EXTENSIONA 
T2B ANY TUMOUR WITH PARAPHARYNGEAL EXTENSION 
T3 TUMOUR INVOLVES BONY STRUCTURES AND/OR PARANASAL SINUSES 
T4 TUMOUR WITH INTRACRANIAL EXTENSION AND/OR INVOLVEMENT OF CRANIAL NERVES, 
INFRATEMPORAL FOSSA, HYPOPHARYNX, ORBIT OR MASTICATOR SPACE 
REGIONAL LYMPH NODE (N) 
NX REGIONAL LYMPH NODES CANNOT BE ASSESSED 
N0 NO REGIONAL LYMPH NODE METASTASIS 
N1 UNILATERALB METASTASIS IN LYMPH NODE(S), 6 CM OR LESS IN THE GREATEST DIMENSION, 
ABOVE THE SUPRACLAVICULAR FOSSAB 
N2 BILATERALB METASTASIS IN LYMPH NODE(S), 6 CM OR LESS IN THE GREATEST DIMENSION, 
ABOVE THE SUPRACLAVICULAR FOSSA 
N3 METASTASIS IN LYMPH NODE(S),>6 CM AND/OR INVOLVE THE SUPRACLAVICULAR FOSSA 
N3A GREATER THAN 6 CM IN DIMENSION 
N3B EXTENSION TO THE SUPRACLAVICULAR FOSSA 
METASTASIS (M) 
MX DISTANT METASTASIS CANNOT BE ASSESSED 
M0 NO DISTANT METASTASIS 
M1 DISTANT METASTASIS 
STAGE GROUPING 
STAGE 0 TIS N0 M0 
STAGE I T1 N0 M0 
STAGE IIA T2A N0 M0 
STAGE IIB T1-2A N1 M0 
  T2B N0-1 M0 
STAGEIII T1-2B N2 M0 
  T3 N0-2 M0 
STAGE IVA T4 N0-2 M0 
STAGE IVB ANY T N3 M0 
STAGE IVC ANY T ANY N M1 
APARAPHARYNGEAL EXTENSION DENOTES POSTEROLATERAL INFILTRATION OF TUMOUR BEYOND THE PHARYNGOBASILAR FASCIA. 
BSUPRACLAVICULAR FOSSA IS A TRIANGULAR AREA ORIGINALLY DESCRIBED BY HO. IT IS DEFINED BY THREE POINTS: (1) THE SUPERIOR MARGIN OF THE STERNAL END OF THE CLAVICLE; (2) THE SUPERIOR 
MARGIN OF THE LATERAL END OF THE CLAVICLE; (3) THE POINT WHERE THE NECK MEETS THE SHOULDER. UNILATERAL OR BILATERAL LYMPH NODES RATHER THAN IPSILATERAL OR CONTRALATERAL LYMPH 
NODES ARE NOTED, AS THE NASOPHARYNX IS CONSIDERED A MIDLINE STRUCTURE. 
Table 1.1:  Table shows the AJCC stage classification for NPC (Woo and Van Hasselt, 
2008) 
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1.5.5 Aetiology and risk factor of NPC 
The development of NPC is contributed by several factors such as genetic factors, 
Epstein - Barr virus (EBV) infection and exposure to environmental carcinogens. 
The historical finding of EBV genome was first discovered by Laing in 1969 (Laing, 
1969) and nowadays researchers have discovered that the EBV genome is frequently 
detected in the biopsy of NPC suggesting the EBV infection plays a pivotal role in 
tumorigenesis (zur Hausen et al., 1970). NPC appears to be related to the viral 
infection as patients develop an antibody response to the viral caspid antigen (VCA), 
the early antigen (EA) and the nuclear antigen (EBNA) (Watkinson et al., 2000). 
Chien et. al. found that two specific serologic markers of EBV infection such as IgA 
antibodies and anti-EBV DNase antibodies can appear long before the development 
of NPC which allows for early detection of NPC in high-risk population (Chien et 
al., 2001b).  
 
Previous studies on NPC have shown that NPC tumorigenesis is closely related to 
environmental factor such as consumption of smoked and preserved foods, exposure 
to soot and dust and occupational exposure to formaldehyde and various herbal oils 
containing Epstein-Barr Virus (EBV) activating compounds (Yu and Yuan, 2002, 
Chen et al., 1999, Feng et al., 2007). In Hong Kong and Southern China, NPC was 
common among fisher folk whose diet is high in salted fish, preserved food which 
lacks fresh vegetables (Watkinson et al., 2000), fruit and deficient of vitamin C such 
as dried fish, salted duck eggs, salted mustard green and fermented soya bean paste 
(Watkinson et al., 2000). Salted fish contains volatile nitrosamines (Watkinson et al., 
2000, Woo and Van Hasselt, 2008) which are alkylating agents and known to induce 
malignant nasal tumors (Yu et al., 1986). Continuous consumption of salted fish 
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among emigrant Chinese showed the high incidence of NPC cases (Woo and Van 
Hasselt, 2008). 
Genetic factor plays an important role for developing NPC. Yu et. al. described that 
the incidence of developing NPC in the first degree relatives of patients is six times 
higher than in normal individuals (Yu et al., 1990). Two areas of genetic that have 
been examined in the study of NPC include human leucocyte antigen (HLA) typing 
and chromosomal level which is related to oncogenes and tumour suppressor genes. 
In this study, we were interested to study the genetic changes at the chromosomal 
level. Previous study in other countries have reported consistent chromosomal 
abnormalities such as deletion in chromosomes 3 and 9 and gain in chromosomes 1 
and 12 (Chien et al., 2001a, Hui et al., 1999) observed in NPC biopsies suggesting 
the NPC tumour suppressor gene and oncogenes occur at these gene loci (Woo and 
Van Hasselt, 2008).   
 
1.6 Identification of Genetic Alterations  
Many techniques can be utilized to identify genetic alterations such as Comparative 
Genomic Hybridization (CGH), Fluorescence In Situ Hybridization (FISH), Single 
Nucleotide Polymorphism array (SNP array), allele-specific Polymerase Chain 
Reactions (allele-specific PCR), Loss of Heterozygosity (LOH) analysis and 
sequencing (Weiss et al., 1999). Compared with other techniques, CGH is a 
technique that provides a global overview of chromosomal gain and losses 
throughout the whole genome from a tumour sample (Weiss et al., 1999). 
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1.7 Comparative Genomic Hybridization (CGH) Technique 
Comparative Genomic Hybridization (CGH) is a molecular cytogenetic technique 
that allows comprehensive analysis throughout the entire tumour genome for regions 
of DNA sequences to detect gain and losses without the need of cell culture 
(Kallioniemi et al., 1992). The technique provides the important benefit of 
application for basic research and clinical practice especially in the area of tumour 
genetics. This is because DNA copy number aberrations are an important pathogen in 
cancer research (Tachdjian et al., 2000) where it can detect amplified genes and 
locate their location on normal chromosomes (Joos et al., 1995). Moreover, in 
clinical genetics, CGH can diagnose unbalanced chromosomal rearrangement (Levy 
and Hirschhorn, 2002) . CGH was first reported in 1992 by Kallioniemi et. al. as a 
new chromosomal analysis technique. This is followed by another report by Manoir 
et al in 1993 (Weiss et al., 1999, Kallioniemi et al., 1992, du Manoir et al., 1993).  
 
According to Weiss et. al., from 1992 to 1999, approximately 300 articles on CGH 
that been published around the world including reviews and technical papers (Figure 
1.6) (Weiss et al., 1999). The CGH method become famous among researchers 
around the world because the many reasons: modified technique in CGH which does 
not need cell culturing, the delay in diagnosis of conventional cytogenetics (Zudaire, 
2002), poor quality of metaphases obtained from solid tumour compared to obtained 
from blood and bone marrow (James, 1999), reduced demands on the material used 
for CGH which made it possible to use archival formalin fixed and paraffin 
embedded materials, smaller lesion, (Weiss et al., 1999) and solid tumours (Zudaire, 
2002).  
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1.7.1 Principles of CGH 
CGH is a modified method from in situ hybridization (Kallioniemi et al., 1994). 
DNA which is used in CGH method, is independent of tumour cell growth, will give 
invaluable information on genetic alteration in many types of solid tumours. 
According to Kallioniemi et. al., who is the developer for this technique, 
approximately equal amounts of labelled DNA was used. Green fluorochrome is 
labelled to the test DNA and red fluorochrome is labelled to the normal DNA. There 
were then cut into small fragments before hybridized to normal metaphase spread 
with the presence of Human Cot-1 DNA to block the repetitive sequences. The 
metaphase chromosomes are first fixed conventionally to the slide which is used as a 
targeted DNA (Tachdjian et al., 2000). Both green and red DNA fragments will 
compete during hybridization to their locus of origin on the chromosomes on the 
metaphase slide (Kallioniemi et al., 1994). After hybridization for 2 to 3 days, the 
images of the metaphases were captured by fluorescence microscope and analyzed 
using CGH software (Kallioniemi et al., 1994). The green to red ratio represents the 
aberration in the chromosome where underrepresentations (ratio< 1) indicates loss in 
the chromosomes while over-representation (ratio > 1) indicates gain in the 
chromosomes (Figure 1.7) (Weiss et al., 1999). According to Lucille Voullaire and 
Leeanda Wilton the basic assumption in CGH is that the hybridization kinetics of the 
test and reference DNA are independent. Therefore, the ratio of binding of the DNA 
is proportional to the ratio of the copy numbers of the sequences in the DNA samples 
at a specific locus (Voullaire and Wilton, 2007).  The relative amounts of test and 
reference DNA hybridizing to the target DNA are estimated by measuring the green 
and red fluorescence intensities at each point on the target metaphase chromosomes 
using fluorescence microscopy and digital image analysis through green and red 
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filters, respectively (Tachdjian et al., 2000).The regions of the copy number change 
are determined by the relative fluorescence intensities of the test DNA to the 
references DNA hybridized to metaphase chromosomes (Voullaire and Wilton, 
2007). Comparison of the test fluorescence signals and the references fluorescence 
signals allow the detection of chromosomal gains and losses (Zudaire, 2002). 
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Figure 1.6: Graph shows the number of publications using CGH from 1992 to 1998 
(Weiss et al., 1999). 
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Figure 1.7: Schematic diagram shows an overview of principle of CGH (Weiss et 
al., 1999). 
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1.7.2 Application of CGH in cancer research 
CGH is a useful technique that is beneficial in cancer research. There are many 
application of CGH including screening of tumours for genetic aberrations (Chien et 
al., 2001a, Fang et al., 2001, Chen et al., 1999, Hui et al., 1999, Yan et al., 2001), 
searching for genes involved in the carcinogenesis of cancers (Simon et al., 1998) 
and analyzing tumours in experimental models to obtain an insight into tumour 
progression (Tienari et al., 1998). Moreover CGH can also be applied in diagnostic 
classification (Simon et al., 1998) and prognostic assessment (Isola et al., 1995). 
CGH has also been used to study chromosomal alterations in neonatal genomes 
(Daniely et al., 1998, Yu et al., 1997, Wang et al., 1995). 
 
1.7.3 CGH findings in NPC 
There are many studies of NPC using CGH technique around the world especially in 
Asia such as China and Taiwan (Hui et al., 1999, Chien et al., 2001a, Chen et al., 
1999, Fang et al., 2001, Yan et al., 2001) . Research has shown many chromosomal 
alterations gains and losses in NPC patients in their respective countries (Table 1.2). 
Since many studies showed evidence of chromosomal loss at chromosome arm 3p21 
and chromosomal gain at chromosome arm 12p12, therefore, this study will focus on 
chromosome arm 3p21 and 12p12. 
 
 
 
 
 
